RxSight price target lowered to $6.50 from $8 at BofA
BofA lowered the firm's price target on RxSight to $6.50 from $8 and keeps an Underperform rating on the shares. The firm notes the company pre-announced preliminary Q2 sales of $27M vs Street of $32M and lowered 2026 guidance by $13M at midpoint. RxSight pointed to elevated levels of competitive trialing and lower consumer sentiment. The company also announced a strategic collaboration with ALC to develop and commercialize light-adjustable PCIOLs using RxSight's LAL technology. The partnership allows RxSight to leverage its technology in an area it doesn't participate in today, but the path for the collaboration products will likely take a few years, argues BofA.
BofA lowered the firm's price target on RxSight to $6.50 from $8 and keeps an Underperform rating on the shares.
The firm notes the company pre-announced preliminary Q2 sales of $27M vs Street of $32M and lowered 2026 guidance by $13M at midpoint.
RxSight pointed to elevated levels of competitive trialing and lower consumer sentiment.
The company also announced a strategic collaboration with ALC to develop and commercialize light-adjustable PCIOLs using RxSight's LAL technology.
The partnership allows RxSight to leverage its technology in an area it doesn't participate in today, but the path for the collaboration products will likely take a few years, argues BofA.